TRIB3 and acute promyelocytic leukemia: It disrupts the TRIB3-SQSTM1 or TRIB3-PML/RAR α interaction through specific peptides, and this is a potential strategy for treating certain solid cancers and acute promyelocytic leukemia (Hua et al., 2011; Li K. et al., 2017).